At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 1, 2026 at 12:30 ET
Rhythm Pharmaceuticals announced additional positive 52-week data from its Phase 3 TRANSCEND trial showing a -18.8% placebo-adjusted BMI reduction for setmelanotide in patients with acquired hypothalamic obesity (HO), supporting its supplemental New Drug Application (sNDA) currently under FDA review with a PDUFA decision date of March 20, 2026. The data include Japanese and supplemental cohorts, strengthening the clinical package ahead of regulatory decisions in the U.S., EU, and planned submission in Japan.
- Setmelanotide showed a -18.8% placebo-adjusted difference in BMI reduction at 52 weeks in 142 patients with acquired hypothalamic obesity.
- Primary endpoint: -16.4% mean BMI reduction from baseline in setmelanotide group vs. +2.4% in placebo (p<0.0001).
- In patients aged 12+, setmelanotide reduced weekly average most hunger score by 2.5 points vs. 1.3 in placebo (p=0.0015).
- FDA PDUFA goal date for sNDA is March 20, 2026; final data package to be submitted March 2, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access